Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Assumptions of Survival Analysis

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Introduction To Survival Analysis

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time until a...

Survival Curves

Survival Curves

Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy.

Journal of cutaneous medicine and surgery·2026

Same author

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.

Dermatology and therapy·2026

Same author

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

JAMA dermatology·2026

Same author

Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.

Dermatology and therapy·2025

Same author

Bacteriophage therapy in dermatology: A systematic review.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Same author

Drug-Induced Generalized Pustular Psoriasis: A Systematic Review.

Journal of cutaneous medicine and surgery·2025

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

An Optimized Protocol for Candida albicans Infection in Schmidtea mediterranea to Study Fungal Pathogenesis and Host Defense

An Optimized Protocol for Candida albicans Infection in Schmidtea mediterranea to Study Fungal Pathogenesis and Host Defense

Published on: April 17, 2026

Biologic survival.

Kristin Noiles¹, Ronald Vender

¹Michael G. DeGroote School of Medicine. Kristin.noiles@medportal.ca

Journal of Drugs in Dermatology : JDD

|April 15, 2009

Summary

Biologic therapies for psoriasis show promising long-term patient retention. Etanercept demonstrated the lowest discontinuation rates in clinical trials, suggesting potential superior efficacy and safety for psoriasis patients.

Area of Science:

Dermatology
Pharmacology

Background:

Biologic therapies are increasingly used for psoriasis treatment.
Long-term studies reveal promising efficacy and safety profiles for biologics.
High patient retention in clinical trials suggests additional benefits of these treatments.

Purpose of the Study:

To compare attrition rates among various biologic therapies for psoriasis.
To assess and compare patient adherence to long-term biologic treatment (biologic survival).

Main Methods:

Conducted an in-depth literature review using PubMed and MEDLINE.
Analyzed randomized, controlled trials of biologic monotherapy for psoriasis.
Selected and compared studies with patient retention data for at least 24 weeks.

More Related Videos

Quantifying Yeast Chronological Life Span by Outgrowth of Aged Cells

Quantifying Yeast Chronological Life Span by Outgrowth of Aged Cells

Published on: May 6, 2009

A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb (BCG lux/M.Tb lux)

A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb (BCG lux/M.Tb lux)

Published on: September 14, 2011

Related Experiment Videos

Last Updated: Jun 24, 2026

An Optimized Protocol for Candida albicans Infection in Schmidtea mediterranea to Study Fungal Pathogenesis and Host Defense

An Optimized Protocol for Candida albicans Infection in Schmidtea mediterranea to Study Fungal Pathogenesis and Host Defense

Published on: April 17, 2026

Quantifying Yeast Chronological Life Span by Outgrowth of Aged Cells

Quantifying Yeast Chronological Life Span by Outgrowth of Aged Cells

Published on: May 6, 2009

A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb (BCG lux/M.Tb lux)

A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb (BCG lux/M.Tb lux)

Published on: September 14, 2011

Main Results:

Nineteen trials were analyzed to compare attrition rates of different biologic therapies.
Etanercept showed the highest patient retention across studies.
Difficult to definitively conclude due to variations in study design, sample size, and dosing.

Conclusions:

Preliminary data suggest etanercept has the lowest discontinuation rate among biologics for psoriasis.
This may be attributed to etanercept's superior efficacy and favorable safety profile.
Further research is needed due to limited data on patient retention for biologic therapies.